Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticlePsoriatic Arthritis

Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials

Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman and Arthur Kavanaugh for the PSUMMIT 1 and 2 Study Groups
The Journal of Rheumatology November 2019, 46 (11) 1458-1461; DOI: https://doi.org/10.3899/jrheum.180792
Iain B. McInnes
From the University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow Biomedical Research Centre, Glasgow, Scotland; Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York; University of Rochester, Medical Center, Rochester, New York; Janssen Research & Development LLC, Spring House, Pennsylvania; Janssen Scientific Affairs LLC, Horsham, Pennsylvania, USA; Memorial University, St. John’s, Newfoundland and Labrador, Canada; University of California-San Diego, San Diego, California, USA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: Iain.McInnes@glasgow.ac.uk
Lluís Puig
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice B. Gottlieb
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher T. Ritchlin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael Song
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yin You
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shelly Kafka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
G. James Morgan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Proton Rahman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Arthur Kavanaugh
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among patients with psoriatic arthritis (PsA) who are naive to anti–tumor necrosis factor agents.

Methods. In PSUMMIT 1 and 2, patients with PsA were randomized to placebo or ustekinumab 45 mg or 90 mg. Enthesitis was assessed at weeks 0 and 24 (Maastricht Ankylosing Spondylitis Enthesitis Score). Assessments included Health Assessment Questionnaire–Disability Index (HAQ-DI), Medical Outcomes Study Short Form-36 (SF-36) physical component summary/mental component summary (PCS/MCS), and American College of Rheumatology 20 (ACR20).

Results. At Week 24, 21 had worsened enthesitis, 158 had improved enthesitis, and 412 had unchanged enthesitis. Improved enthesitis was associated with improvements in HAQ-DI and SF-36 MCS. Results were similar for ACR20 responders and nonresponders.

Conclusion. Improvement in enthesitis at Week 24 was associated with improvements in physical function/HRQOL regardless of ACR20 response.

Key Indexing Terms:
  • USTEKINUMAB
  • PSORIATIC ARTHRITIS
  • ENTHESITIS
  • HEALTH-RELATED QUALITY OF LIFE

Enthesitis, inflammation at the insertion of tendons, ligaments and joint capsules, is a common manifestation of psoriatic arthritis (PsA)1. Pain arising from enthesitis has been associated with increased pain scores overall and a worsened quality of life compared with patients who do not have enthesitis2. In the phase III PSUMMIT 13 and PSUMMIT 24 trials, patients with PsA who received ustekinumab had significantly greater improvement in the signs and symptoms of PsA, including enthesitis, than did patients who received placebo. Moreover, ustekinumab-treated patients had greater improvement in physical function and health-related quality of life (HRQOL). To further examine the relationship between enthesitis and physical function and HRQOL, we performed a posthoc analysis using combined data from the PSUMMIT trials.

MATERIALS AND METHODS

Patients and study design

The patient inclusion criteria and study designs for the PSUMMIT 13 and PSUMMIT 24 trials have been previously described. Briefly, in both studies, adults were eligible if they had active PsA for ≥ 6 months despite ≥ 3 months of therapy with disease-modifying antirheumatic drugs or ≥ 4 weeks of therapy with nonsteroidal antiinflammatory drugs, or intolerance to these therapies. PSUMMIT 1 included only biologic-naive patients; in PSUMMIT 2, prior therapy with an anti–tumor necrosis factor (TNF) agent for ≥ 8 weeks (etanercept, adalimumab, golimumab, or certolizumab pegol) or ≥ 12 weeks (infliximab) was permitted. In both trials, eligible patients were randomized to receive subcutaneous injections of placebo, ustekinumab 45 mg, or ustekinumab 90 mg at weeks 0 and 4 and every 12 weeks thereafter. Patients in the placebo group crossed over to ustekinumab 45 mg at Week 24. At Week 16, patients with < 5% improvement from baseline in both tender and swollen joint counts entered double-blind early escape, such that patients in the placebo group received ustekinumab 45 mg, and patients in the ustekinumab 45 mg group received ustekinumab 90 mg; patients in the ustekinumab 90 mg group did not have any adjustments in study treatment regardless of early escape status.

Both PSUMMIT 1 (NCT01009086) and PSUMMIT 2 (NCT01077362) were conducted in accordance with Good Clinical Practices and the Declaration of Helsinki. The protocol was approved by the ethics committee or institutional review board (IRB) at each site. Patients were required to give written informed consent before study-related procedures were performed. Centralized IRB approval was managed primarily by Copernicus Group IRB in the United States (approval numbers: PSUMMIT 1, CEN1-09-416; PSUMMIT 2, CEN-09-487) and Research Review Board in Canada (approval numbers: PSUMMIT 1, 2009.275; PSUMMIT 2, 2009.288).

Assessments

In the PSUMMIT studies, enthesitis was assessed using the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) index5. Enthesitis at each site recorded in the MASES instrument was scored only as either present or absent in each site. Physical function was evaluated using the Health Assessment Questionnaire–Disability Index (HAQ-DI), and general HRQOL was assessed using the Medical Outcomes Study Short Form-36 (SF-36) physical and mental component summary (PCS and MCS, respectively) scores. The proportion of patients with ≥ 20% improvement in the American College of Rheumatology criteria (ACR20)6 was determined at Week 24 to assess overall clinical response.

Statistical analysis

In this posthoc analysis, to have adequate sample size, patients from both studies were included. The population was limited to patients who were biologic-naive (all 615 patients in PSUMMIT 1 and 132 of 312 patients in PSUMMIT 2). This analysis excluded patients who met the early escape criteria and those who did not have enthesitis data available at either baseline or Week 24. Thus, data from 591 patients (PSUMMIT 1, n = 493; PSUMMIT 2, n = 98) were analyzed. The number of body sites with enthesitis was assessed at baseline and Week 24, and categorized as worsened (greater number of sites with enthesitis present at Week 24), improved (fewer sites with enthesitis present at Week 24), or unchanged (same number of sites with enthesitis present at both baseline and Week 24 or no enthesopathy present at both baseline and Week 24). Patients with missing data at either Week 0 (placebo, n = 1; combined ustekinumab, n = 1) or Week 24 (placebo, n = 21; combined ustekinumab, n = 19) were included in the unchanged category.

RESULTS

A total of 591 patients (PSUMMIT 1, n = 493; PSUMMIT 2, n = 98) were included in this analysis (Table 1). The proportion of patients with enthesitis at baseline was similar between the placebo group (72.3%) and the combined ustekinumab group (72.2%). At Week 24, 21 patients (placebo, n = 10; ustekinumab, n = 11) had a worsened enthesitis status relative to baseline, and 158 patients (placebo, n = 33; ustekinumab, n = 125) had an improved enthesitis status (Table 2). A total of 412 patients (placebo, n = 134; ustekinumab, n = 278) were classified as unchanged; 131 patients (placebo, n = 34; ustekinumab, n = 97) did not have enthesitis at both baseline and Week 24; 239 (placebo, n = 78; ustekinumab, n = 161) had enthesitis at both baseline and Week 24, and 42 patients had missing data either at baseline (n = 2) or Week 24 (n = 40). Among all patients, 44.8% were female, and the mean age was 47 years. Baseline demographic and disease characteristics were generally similar among the 3 enthesitis status groups (Table 1). Among patients with worsened or unchanged enthesitis, distal interphalangeal joint arthritis was more common when compared with patients who had improved enthesitis (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Baseline demographic and disease characteristics of biologic-naive patients from PSUMMIT 1 and PSUMMIT 2.

View this table:
  • View inline
  • View popup
Table 2.

Changes in HAQ-DI, SF-36 PCS, and SF-36 MCS at Week 24 among patients with improved, worsened, or unchanged enthesitis.

The mean percent improvement in HAQ-DI score at Week 24 was greater among patients with improved enthesitis (42.0%) compared with patients whose enthesitis was worsened (19.3%; p = 0.030) or unchanged (19.6%; p < 0.001). The mean change in SF-36 PCS score at Week 24 for patients with improved enthesitis (7.0) was greater than that in the unchanged group (4.6; p < 0.001) and numerically greater than that in the worsened group (5.2; p = 0.425); however, this difference did not meet statistical significance. The mean change in SF-36 MCS score was greater for patients with improved enthesitis (4.8) compared with patients in the worsened group (−1.1; p = 0.010); the mean change in SF-36 MCS score in the unchanged enthesitis group was numerically lower, but did not reach statistical significance (4.1; p = 0.155; Table 2).

At Week 24, the mean percent improvement in HAQ-DI and mean improvement in SF-36 PCS score were greater in patients who achieved an ACR20 response compared with ACR20 nonresponders in all 3 enthesitis subgroups (Figure 1). Mean changes in SF-36 MCS score were similar between ACR20 responders and nonresponders for patients with worsened or improved enthesitis. For patients with unchanged enthesitis, ACR20 responders had a greater mean improvement in SF-36 MCS score than did ACR20 non-responders. Among ACR20 responders, improvements in HAQ-DI and SF-36 PCS scores were numerically greater for patients with improved enthesitis compared with those with worsened or unchanged enthesitis (Figure 1). A similar trend was observed for improvements in HAQ-DI and SF-36 MCS among ACR20 nonresponders; however, mean changes in SF-36 PCS scores were similar among the 3 enthesitis subgroups for ACR20 nonresponders (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Percent change from baseline in HAQ-DI (A), mean change from baseline in SF-36 PCS score (B), and mean change from baseline in SF-36 MCS score (C) for ACR20 responders and ACR20 nonresponders with an enthesitis status of worsened, unchanged, or improved at Week 24. ACR20: ≥ 20% improvement in the American College of Rheumatology criteria; HAQ-DI: Health Assessment Questionnaire–Disability Index; SF-36 PCS/MCS: Medical Outcomes Study Short Form-36 Health Survey physical/mental component summary.

DISCUSSION

It has been estimated that over one-third of patients with PsA experience enthesitis1. Enthesitis has been associated with greater peripheral joint damage and axial damage7 and has also been associated with increased HAQ-DI scores, pain, and fatigue as well as greater work impairment2. In this exploratory analysis of anti–TNF-naive patients with PsA from the PSUMMIT 1 and PSUMMIT 2 trials, improvement in enthesitis was associated with improvements in physical function and HRQOL at Week 24. Patients who achieved an ACR20 response generally had greater improvements in physical function and HRQOL than did ACR20 nonresponders. However, patients with improvement in enthesitis had numerically greater improvements in HAQ-DI scores compared with those who had unchanged or worsened enthesitis, regardless of ACR20 response. Thus, some patients may still receive clinical benefit from treatment despite not reaching an ACR20 response. This emphasizes the need to consider the distinct tissue compartments that characterize the clinical phenotypes prevalent in a PsA clinic8.

These results are limited by the exploratory nature of the analysis and the relatively small numbers of patients in some groups; the PSUMMIT 1 and 2 trials were not powered for these comparisons. Additionally, the assessment of enthesitis in this analysis was limited to the presence or absence of enthesitis and did not reflect absolute changes in score. However, these results provide insight into the role of enthesitis in HRQOL and physical function in PsA, which is important for patients and their clinicians.

Acknowledgment

The authors thank Kezhen L. Tang, PhD (Janssen Research & Development LLC), for statistical support, and Rebecca E. Clemente, PhD (Janssen Scientific Affairs LLC), for writing support.

Footnotes

  • This study was funded by Janssen Research & Development LLC. Janssen Biotech Inc. manufactures ustekinumab.

  • IBM has received consulting fees from AbbVie, Janssen, Novartis, Pfizer, and UCB. LP has received consulting fees or speaker fees or served as an investigator or advisory board member for AbbVie, Almirall, Amgen, Baxalta, Biogen, Boehringer-Ingelheim, Celgene, Gebro, Janssen, Leo-Pharma, Lilly, Merck-Serono, MSD, Novartis, Pfizer, Regeneron, Roche, Sandoz, and SUN Pharmaceutical Industries. ABG has received consulting fees and served as an advisory board member for AbbVie, Janssen, Lilly, Novartis, and UCB, and has received research/educational grants from Janssen, Novartis, and UCB. CTR has received research grants, consulting fees, or speaker honoraria from AbbVie, Amgen, Janssen, Novartis, and UCB. AK has received consulting fees and research support from AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. PR has received consulting fees from Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Lilly, Novartis, Pfizer, and Roche. SK and GJM are or were employees of Janssen Scientific Affairs LLC when this work was performed and own stock in Johnson & Johnson, of which Janssen Research & Development LLC is a wholly-owned subsidiary. MS and YY are employees of Janssen Research & Development LLC, and own stock in Johnson & Johnson.

  • Accepted for publication March 19, 2019.

REFERENCES

  1. 1.↵
    1. Polachek A,
    2. Li S,
    3. Chandran V,
    4. Gladman DD
    . Clinical enthesitis in a prospective longitudinal psoriatic arthritis cohort: incidence, prevalence, characteristics, and outcome. Arthritis Care Res 2017;69:1685–91.
    OpenUrl
  2. 2.↵
    1. Mease PJ,
    2. Karki C,
    3. Palmer JB,
    4. Etzel CJ,
    5. Kavanaugh A,
    6. Ritchlin CT,
    7. et al.
    Clinical characteristics, disease activity, and patient-reported outcomes in psoriatic arthritis patients with dactylitis or enthesitis: results from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry. Arthritis Care Res 2017;69:1692–9.
    OpenUrl
  3. 3.↵
    1. McInnes IB,
    2. Kavanaugh A,
    3. Gottlieb AB,
    4. Puig L,
    5. Rahman P,
    6. Ritchlin C,
    7. et al.
    Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013;382:780–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Ritchlin C,
    2. Rahman P,
    3. Kavanaugh A,
    4. McInnes IB,
    5. Puig L,
    6. Li S,
    7. et al.
    Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. Ann Rheum Dis 2014;73:990–9.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Heuft-Dorenbosch L,
    2. Spoorenberg A,
    3. van Tubergen A,
    4. Landewe R,
    5. van der Tempel H,
    6. Mielants H,
    7. et al.
    Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003;62:127–32.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Felson DT,
    2. Anderson JJ,
    3. Boers M,
    4. Bombardier C,
    5. Furst D,
    6. Goldsmith C,
    7. et al.
    American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727–35.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Polachek A,
    2. Cook R,
    3. Chandran V,
    4. Gladman DD,
    5. Eder L
    . The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. Arthritis Res Ther 2017;19:189.
    OpenUrl
  8. 8.↵
    1. Cafaro G,
    2. McInnes IB
    . Psoriatic arthritis: tissue-directed inflammation? Clin Rheumatol 2018;37:859–68.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 46, Issue 11
1 Nov 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman, Arthur Kavanaugh
The Journal of Rheumatology Nov 2019, 46 (11) 1458-1461; DOI: 10.3899/jrheum.180792

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials
Iain B. McInnes, Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman, Arthur Kavanaugh
The Journal of Rheumatology Nov 2019, 46 (11) 1458-1461; DOI: 10.3899/jrheum.180792
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgment
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Keywords

USTEKINUMAB
PSORIATIC ARTHRITIS
ENTHESITIS
HEALTH-RELATED QUALITY OF LIFE

Related Articles

Cited By...

More in this TOC Section

  • Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
  • Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
  • Canadian Adalimumab Postmarketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis (COMPLETE-PsA): 12-month Results of Comparative Effectiveness of Adalimumab and nbDMARDs
Show more Psoriatic Arthritis

Similar Articles

Keywords

  • ustekinumab
  • psoriatic arthritis
  • ENTHESITIS
  • health-related quality of life

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire